-
-
-
[1] CREUTZIG U,VAN DEN HEUVEL-EIBRINK M M,GIBSON B,et al.Diagnosis and management of acute myeloid leukemia in children and adolescents:recommendations from an international expert panel[J].Blood,2012,120:3187-3205.
[2] OFRAN Y,ROWE J M.Treatment for relapsed acute myeloid leukemia:what is new?[J].Curr Opin Hematol,2012,19:89-94.
[3] MANGAN J K,LUGER S M.Salvage therapy for relapsed or refractory acute myeloid leukemia[J].Ther Adv Hematol,2011,2:73-82.
[4] WEI G,NI W,CHIAO J W,et al.A meta-analysis of CAG (cytarabine,aclarubicin,G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J].J Hematol Oncol,2011,4:46.
[5] FADERL S,WETZLER M,RIZZIERI D,et al.Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia[J].J Clin Oncol,2012,30:2492-2499.
[6] HOROWITZ M M,ROWLINGS P A.An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Bone Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation[J].Curr Opin Hematol,1997,4:395-400.
[7] KUROSAWA S,YAMAGUCHI T,MIYAWAKI S,et al.Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse[J].Haematologica,2010,95:1857-1864.
[8] DUVAL M,KLEIN J P,HE W,et al.Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure[J].J Clin Oncol,2010,28:3730-3738.
[9] SCHMID C,SCHLEUNING M,SCHWERDTFEG-ER R,et al.Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation[J].Blood,2006,108:1092-1099.
[10] FELDMAN E J,GERGIS U.Management of refractory acute myeloid leukemia:re-induction therapy or straight to transplantation?[J].Curr Hematol Malig Rep,2012,7:74-77.
[11] COWAN A J,LASZLO G S,ESTEY E H,et al.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin[J].Front Biosci (Landmark Ed),2013,18:1311-1334.
[12] GANETSKY A.The role of decitabine for the treatment of acute myeloid leukemia[J].Ann Pharmacother,2012,46:1511-1517.
[13] BORTHAKUR G,KANTARJIAN H,RAVANDI F,et al.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias[J].Haematologica,2011,96:62-68.
[14] ATTAR E C,JOHNSON J L,AMREIN P C,et al.Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years:CALGB (Alliance) study 10502[J].J Clin Oncol,2013,31:923-929.
[15] YOM-TOV G,NATHAN I,SHPILBERG O,et al.Clomiphene as a novel modality for the treatment of acute myeloid leukemia:A pilot phase II study[J].Leuk Res,2012,36:42-45.
[16] UNGEWICKELL A,MEDEIROS B C.Novel agents in acute myeloid leukemia[J].Int J Hematol,2012,96:178-185.
-
计量
- 文章访问数: 32
- PDF下载数: 775
- 施引文献: 0
下载: